Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ...
Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, ...
The developer of Relay for Reddit shared potential subscription prices, and they’ll vary based on your daily average of API calls. The developer of Relay for Reddit shared potential subscription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback